This study is testing a drug called telitacicept for people with generalized myasthenia gravis (gMG), an autoimmune disease that causes muscle weakness. Telitacicept works by targeting certain proteins that help B cells (a type of immune cell) grow and mature, which may help reduce autoimmune symptoms. You might receive telitacicept or a placebo (an inactive substance) as a shot under the skin. The main goal is to see how much your Myasthenia Gravis-Activities of Daily Living (MG-ADL) score changes after 24 weeks. To join, you must be at least 18 years old and have a confirmed diagnosis of gMG. The study is currently not recruiting, and aims to enroll 180 participants.

Study design

This is a randomized, double-blind study, meaning you will be randomly assigned to receive either telitacicept or a placebo, and neither you nor your doctors will know which you are receiving. It is a Phase 3 study, and plans to include 180 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at Week 24, but the study includes an open-label extension, suggesting follow-up beyond this point.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.